Althea and GeoVax Join Hands to Produce AIDS Vaccine

July 24, 2007
BioPharm International Editors

Althea Technologies, Inc. (San Diego, CA, www.altheatech.com), has been contracted by GeoVax Labs, Inc. (Atlanta, GA, www.geovax.com), to manufacturer its HIV-1 DNA vaccine.

Althea Technologies, Inc. (San Diego, CA, www.altheatech.com), has been contracted by GeoVax Labs, Inc. (Atlanta, GA, www.geovax.com), to manufacturer its HIV-1 DNA vaccine. This vaccine will be used in GeoVax’s advanced Phase 2 human trials planned to start in early 2008. GeoVax AIDS vaccines are designed to prevent development of Acquired Immunodeficiency Disease (AIDS) caused by the virus known as HIV-1, by vaccinating individuals before their infection with the AIDS virus. The GeoVax vaccine regimen employs a “prime-boost strategy.”  Trial participants are administered the GeoVax HIV-1 DNA vaccine, which “primes” the immune system, followed by the GeoVax HIV-1 MVA (Modified Vaccinia Virus) boost.

Related Content:

News